The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis

Introduction : In severe exacerbations of COPD and chronic bronchitis accompanied by difficult expectorated purulent sputum there is a need in both antibiotic and mucolytic treatment. Aims : To investigate the efficacy and safety of an original combination drug - inhaled Thiamphenicol Glycinate Acetylcysteinate (Fluimucil-antibiotic-IT) 500 mg daily. Methods : 15 patients with acute exacerbation of COPD (phenotype of airways disease) and 10 patients with acute exacerbation of chronic bronchitis with bronchiectasis were recruited (60% male, with mean age of 59.4±16.0 and %FEV1 64.3±11.5%). Nebulized Fluimucil-antibiotic-IT was administrated 250 mg BID for 6 days. At baseline and after 6 days respiratory symptoms severity, inflammation markers, sputum culture were assessed and adverse events were collected. Results : After 6 days of treatment it was noted decrease the severity of sputum production (4 vs 1.5, p Conclusions : Fluimucil-antibiotic-IT is effective and safe combination treatment of COPD and chronic bronchitis exacerbations.